Company intelligence / Profile preview
Anivive Lifesciences
- Ownership
- Private
- Development stage
- Other
Overview
Anivive has developed the first oral pill approved to treat canine lymphoma and is advancing a first-in-class antifungal vaccine for Valley Fever in dogs—currently under USDA review—with plans to adapt this technology for human use. The company’s pipeline includes eight+ innovative programs targeting cancer, viral infections like FIP/COVID‑19, fungal diseases such as blastomycosis/Valley Fever, with multiple products approaching commercialization
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinesSmall moleculesAntiviralsBiologics (implied by vaccine and infectious disease focus)
- Industry
- Veterinary
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Anivive Lifesciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anivive Lifesciences.